We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Implications of Amyloid Pathology

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00900770
Recruitment Status : Unknown
Verified December 2009 by National Institute on Aging (NIA).
Recruitment status was:  Recruiting
First Posted : May 13, 2009
Last Update Posted : December 29, 2009
Information provided by:
National Institute on Aging (NIA)

Brief Summary:
The purpose of this study is to determine whether asymptomatic older individuals with high amyloid burden will subsequently manifest cognitive impairment and eventually progress to clinical Alzheimer's Disease (AD).

Condition or disease
Alzheimer's Disease

Detailed Description:

There is compelling evidence supporting amyloid as one of the key pathologic agents in AD. Autopsy studies suggest the amount and location of fibrillar amyloid deposition does not relate strongly to the degree and type of clinical impairment, compared to tau pathology and neuronal loss. A substantial percentage of individuals known to be cognitively intact prior to death demonstrate significant amyloid pathology at autopsy. PIB-PET studies of older normal individuals have also demonstrated significant amyloid deposition in substantial percentages.

This study will test the hypothesis that amyloid is associated with synaptic dysfunction and neuronal damage. While some individuals are able to compensate for amyloid-related toxicity for an extended time period, sensitive imaging and neuropsychological markers will reveal that normal subjects with evidence of high amyloid burden do demonstrate evidence of abnormality consistent with prodromal AD.

The study will use a combination of functional, structural, and cognitive measures to detect early effects of amyloid deposition, and will utilize PIB retention in order to characterize the relationship of amyloid to neuropsychological and imaging markers of prodromal AD. The relationship of PIB retention to genetic, plasma and cerebrospinal fluid (CSF) biomarkers will be explored. These preliminary data will be used to determine whether asymptomatic older individuals with high amyloid burden will subsequently manifest cognitive impairment and eventually progress to clinical AD. When completed, this project will either provide evidence that the presence of amyloid deposition is a useful biomarker for incipient AD or raise the possibility that amyloid deposition examined in isolation is insufficient to predict early symptoms and progression of AD.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Implications of Amyloid Deposition in Clinically Normal Older Individuals
Study Start Date : November 2008
Estimated Primary Completion Date : March 2014
Estimated Study Completion Date : March 2014

PIB positive, cognitively normal individuals with foci of elevated PIB retention in cortical regions typically affected in AD
PIB negative, cognitively normal individuals without amyloid deposition

Primary Outcome Measures :
  1. Pittsburgh Compound B (PiB) and F-18 fluorodeoxyglucose (FDG) PET Scan [ Time Frame: at 1 month ]

Secondary Outcome Measures :
  1. Cognitive and functional assessments [ Time Frame: Baseline and annually for 5 years ]
  2. Lumbar Puncture (optional) [ Time Frame: Baseline ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   60 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Longitudinal cohort of the Massachusetts Alzheimer's Disease Research Center and community volunteers

Inclusion Criteria:

  • Age range from 60 to 90 years
  • Clinical Dementia Rating (CDR) Score of 0
  • Mini Mental State Exam of 27-30
  • A study partner who can answer questions pertaining to daily functioning
  • Perform within 1.5 standard deviation of age and education matched norms on screening tests of attention and executive function, language, visuospatial perception and episodic memory
  • Stable medications for at least 30 days
  • Fluent in English
  • Modified Hachinski Score of <4
  • Geriatric Depression Scale Score <10

Exclusion Criteria:

  • Diagnosis of MCI or dementia
  • Individuals with contraindications to MRI (i.e., implanted metal including pacemakers, cerebral spinal fluid shunts, aneurysm clips, artificial heart valves, ear implants or metal/foreign objects in the eyes and those with a history of claustrophobia)
  • Unstable medications or on medications with CNS effects including cholinesterase inhibitors, memantine, and antidepressants
  • Major psychiatric disorders such as schizophrenia, schizoaffective disorder, major affective disorder, or treatment with ECT (mild depression that is well treated with stable dose of SSRI antidepressants will be allowed)
  • Multiple sclerosis or other autoimmune disorders
  • Huntington's disease
  • Head injury, post-traumatic dementia or seizures
  • Metabolic encephalopathy, CNS infection, hydrocephalus
  • Cardiovascular disease, stroke, congestive heart failure
  • Substance abuse within the past 2 years
  • Active cancer
  • Active hematological, renal, pulmonary, endocrine or hepatic disorders

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00900770

Layout table for location information
United States, Massachusetts
Brigham and Women's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: Kelly O'Keefe    617-726-6212    kokeefe1@partners.org   
Contact: Meghan Frey    617-732-8085    mfrey1@partners.org   
Principal Investigator: Reisa A. Sperling, MD         
Sub-Investigator: Keith A. Johnson, MD         
Sponsors and Collaborators
National Institute on Aging (NIA)
Layout table for investigator information
Principal Investigator: Reisa Sperling, MD Director of Clinical Research, Memory Disorders Unit, Brigham and Women's Hospital
Layout table for additonal information
Responsible Party: Reisa Sperling, MD, Director of Clinical Research, Memory Disorders Unit, Brigham and Women's Hospital
ClinicalTrials.gov Identifier: NCT00900770    
Other Study ID Numbers: IA0158
2P50AG005134 ( U.S. NIH Grant/Contract )
First Posted: May 13, 2009    Key Record Dates
Last Update Posted: December 29, 2009
Last Verified: December 2009
Keywords provided by National Institute on Aging (NIA):
mild cognitive impairment
beta amyloid
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders